MORGAN STANLEY PLC/CALL/GILEAD SCIENCES/75/0.1/21.06.24 | Delayed Börse Stuttgart 19:33:27 31/05/2024 BST | ||
| 0.012 EUR | -.--% |
|
| 1 month | -36.84% | ||
| 3 months | -95.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 31/05/24 | 0.012 | -.--% |
| 30/05/24 | 0.012 | -7.69% |
| 29/05/24 | 0.013 | +30.00% |
| 28/05/24 | 0.01 | -.--% |
| 27/05/24 | 0.01 | -28.57% |
Delayed Quote Börse Stuttgart
Last update May 31, 2024 at 07:33 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | Morgan Stanley |
| WKN | MD7C7N |
| ISIN | DE000MD7C7N2 |
| Date issued | 24/08/2022 |
| Strike | 75 $ |
| Maturity | 21/06/2024 (17 Days) |
| Parity | 10 : 1 |
| Emission price | 0.56 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.05 € |
|---|---|
| Lowest since issue | 0.008 € |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
63.43
USD
Average target price
82.7
USD
Spread / Average Target
+30.38%
- Stock Market
- Warrants
- Warrant